ICICI Direct's research report on Biocon
Biocon is a leading biopharma company operating in biologics, small molecules, branded formulations and contract research. Revenue breakup: Biosimilars (37%), generics (31%), research services (29%)
Biosimilar/Insulin US pipeline- (Launched - Pegfilgrastim, Trastuzumab, Glargine; Aspart (expected in FY22E) and Bevacizumab (delayed)
Outlook
We maintain our HOLD rating on the stock We value Biocon at Rs 400 on SOTP basis
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Read More